logo
Scientists Create Biodegradable Plastic Alternative That's Literally Alive

Scientists Create Biodegradable Plastic Alternative That's Literally Alive

Yahoo2 days ago

Swiss scientists have created a new plastic-like material that's flexible, biodegradable, and even edible. The secret? It's still alive.
The material, which was created by a team from Empa in Switzerland, manages to balance biodegradability with toughness and versatility – a feat that is far from easy in materials science.
The researchers processed fibers from the mycelium (the root-like part) of the split-gill mushroom (Schizophyllum commune) into a liquid mixture, without actually killing them off or destroying their natural biological functions.
The resulting gel-like material is called living fiber dispersions, or LFD, and it can be molded into many different forms. It also makes full use of the extra substances produced by mushrooms, where other biomaterials might just use the core fungal cells.
"The fungus uses this extracellular matrix to give itself structure and other functional properties," says materials scientist Ashutosh Sinha, from Empa. "Why shouldn't we do the same?"
By developing a specific strain of the split-gill, the researchers were able to encourage the growth of two molecules in particular: polysaccharide schizophyllan and hydrophobin. These molecules are crucial in giving LFD its appealing properties.
One possible use of the material is as a thin film with a very high tensile strength. The researchers suggest it could potentially be used in compost bags that naturally rot away as well as composting their contents, or in super-thin biodegradable batteries.
LFD also works well as an emulsifier, a substance that enables two other materials to mix and bind together when they otherwise wouldn't. Emulsifiers are important in food and cosmetics production, found in everything from ice cream to shampoo.
Because it's still alive, the fungus keeps releasing more of its key molecules.
"This is probably the only type of emulsion that becomes more stable over time," says Sinha.
And because it comes from the edible S. commune mushroom, this LFD is completely non-toxic too – you can even eat it without any problems. When it comes to foods and cosmetics, that's another big plus for the material.
There's the potential for plenty of future research here too, because the team thinks that the approach used here could be tweaked to produce materials with other specific properties, like an on-demand materials maker.
Scientists will often look to nature for inspiration, whether they're developing drug delivery methods or building robots, and we're seeing an increasing number of studies investigating fungi as a foundation for new materials.
Fungi-based biomaterials could act as alternatives to plastic, and to form clothes that are able to repair themselves. There's a lot of benefit in materials that combine the natural and the synthetic.
The researchers are hoping to find more and more practical uses for LFD over time, following in a long line of materials inspired by nature – evidence that the natural world around us is the best lab there is.
"Biodegradable materials always react to their environment," says materials scientist Gustav Nyström, from Empa.
"We want to find applications where this interaction is not a hindrance but maybe even an advantage."
The research has been published in Advanced Materials.
Uploading The Human Mind Could Become a Reality, Expert Says
Scientists Developed a Kind of 'Living Concrete' That Heals Its Own Cracks
World's First CRISPR-Edited Spiders Shoot Fluoro Red Silk From Their Butts

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Roche's Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
Roche's Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer

Yahoo

time16 minutes ago

  • Yahoo

Roche's Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer

46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options 1 First Phase III study in ES-SCLC first-line maintenance to demonstrate clinically meaningful improvements in both progression-free and overall survival 2,3 Data were presented in an oral session at the 2025 ASCO Annual Meeting and simultaneously published in The Lancet 1,4 Basel, 3 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III IMforte study of Tecentriq® (atezolizumab) in combination with lurbinectedin (Zepzelca®) as a first-line maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC), following induction therapy with carboplatin, etoposide and Tecentriq. The data showed that this combination reduced the risk of disease progression or death by 46% and the risk of death by 27%, compared to Tecentriq maintenance therapy alone. Safety was consistent with the known safety profiles of Tecentriq and lurbinectedin. These data were presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet.1,4 "Small cell lung cancer is an aggressive and devastating disease. At the time of diagnosis, the large majority of patients have already progressed to extensive-stage disease and only one out of five survive longer than two years', said Luis Paz-Ares, MD, PhD, Head of Medical Oncology at the Hospital Universitario 12 de Octubre in Madrid, Spain, and IMforte trial principal investigator. 'The IMforte results are very encouraging showing a potentially practice-changing option that could improve survival for patients with a very high unmet need.' "In the IMforte study, the Tecentriq and lurbinectedin maintenance regimen significantly extended survival for people living with extensive-stage small cell lung cancer,' said Levi Garraway, MD, PhD, Roche's Chief Medical Officer and Head of Global Product Development. 'This study builds on Tecentriq's well-established safety and efficacy profile as the first immunotherapy for this cancer type and may provide another approach to help physicians and patients better manage this aggressive disease." Patients in the IMforte study first completed four cycles of Tecentriq combined with chemotherapy, over the course of approximately three months, before being randomised into maintenance treatment. From the point of randomisation, the median overall survival (OS) for the Tecentriq plus lurbinectedin regimen was 13.2 months versus 10.6 months for Tecentriq alone (stratified hazard ratio [HR] = 0.73; 95% CI: 0.57–0.95; p = 0.0174). Median progression-free survival (PFS) by independent assessment was 5.4 months versus 2.1 months, respectively (stratified HR = 0.54, 95% CI: 0.43–0.67; p < 0.0001). No new safety signals were observed.1 About the IMforte study IMforte [NCT05091567] is a Phase III, open-label, randomised trial evaluating the efficacy and safety of Tecentriq® (atezolizumab) plus lurbinectedin versus Tecentriq alone as first-line maintenance therapy for adults (≥18 years) with extensive-stage small-cell lung cancer (ES-SCLC). Patients first received induction therapy with Tecentriq, carboplatin and etoposide for four 21-day cycles. Those without disease progression were then randomised 1:1 to receive maintenance therapy with either Tecentriq plus lurbinectedin or Tecentriq alone until disease progression or unacceptable toxicity. The study enrolled 660 patients in the induction phase and randomised 483 patients in the maintenance phase. The study's primary endpoints were independent review facility (IRF)-assessed progression-free survival (PFS) and overall survival (OS) from randomisation into the maintenance phase.1,5 The trial is sponsored by Roche and co-funded by Jazz Pharmaceuticals. About Tecentriq Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells. Tecentriq is approved for some of the most aggressive and difficult-to-treat forms of cancer. Tecentriq was the first cancer immunotherapy approved for the treatment of a certain type of early-stage (adjuvant) NSCLC, small cell lung cancer (SCLC) and hepatocellular carcinoma (HCC). Tecentriq is also approved in countries around the world, either alone or in combination with targeted therapies and/or chemotherapies, for various forms of metastatic NSCLC, certain types of metastatic urothelial cancer (mUC), PD-L1-positive metastatic triple-negative breast cancer (TNBC), BRAF V600 mutation-positive advanced melanoma and alveolar soft part sarcoma (ASPS). In addition to intravenous infusion, Tecentriq has been approved as a subcutaneous injection. About Roche in cancer immunotherapy To learn more about Roche's scientific-led approach to cancer immunotherapy, please follow this link: Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit ZEPZELCA is a trademark of Pharma Mar, S.A. used by Jazz Pharmaceuticals under license. All trademarks used or mentioned in this release are protected by law. References [1] Paz-Ares L, et al. Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. Presented at: ASCO Annual Meeting; 2025 May 30-Jun 03; Chicago, IL, USA. Abstract #8006. [2] Belluomini L, et al. Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis. Seminars in Oncology. 2022; 49(5): 389-393. [3] Roviello G, et al. No advantage in survival with targeted therapies as maintenance in patients with limited and extensive-stage small cell lung cancer: a literature-based meta-analysis of randomized trials. Clin Lung Cancer. 2016; 17(5): 334–340. [4] Paz-Ares L, et al. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2025 Jun 02. [Internet; cited June 2025]. Available from: [5] A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte). [Internet; cited May 2025]. Available from: Roche Global Media Relations Phone: +41 61 688 8888 / e-mail: Hans Trees, PhD Phone: +41 79 407 72 58 Sileia Urech Phone: +41 79 935 81 48 Nathalie Altermatt Phone: +41 79 771 05 25 Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915 Karsten Kleine Phone: +41 79 461 86 83 Nina Mählitz Phone: +41 79 327 54 74 Kirti Pandey Phone: +49 172 6367262 Yvette Petillon Phone: +41 79 961 92 50 Dr Rebekka Schnell Phone: +41 79 205 27 03 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: Attachment 03062025_Phase III IMforte study of Tecentriq_en

Addex Convenes Annual General Meeting 2025
Addex Convenes Annual General Meeting 2025

Yahoo

time41 minutes ago

  • Yahoo

Addex Convenes Annual General Meeting 2025

Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2025 Annual General Meeting will take place on Tuesday June 24, 2025, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). Agenda 1. Approval of the Annual Report, the Annual Financial Statements and the Consolidated Financial Statements for the business year 20242. Consultative vote on the Compensation Report for the business year 20243. Appropriation of the results4. Discharge of the members of the Board of Directors and of the Executive Management5. Re-elections of the members of the Board of Directors and re-election of the Chairman of the Board of Directors5.1. Re-election of Vincent Lawton as member and Chairman of the Board of Directors5.2. Re-election of Raymond Hill as member of the Board of Directors5.3. Re-election of Timothy Dyer as member of the Board of Directors5.4. Re-election of Roger Mills as member of the Board of Directors5.5. Re-election of Jake Nunn as member of the Board of Directors5.6. Re-election of Isaac Manke as member of the Board of Directors6. Re-elections of the members of the Compensation Committee6.1. Re-election of Vincent Lawton as member of the Compensation Committee6.2. Re-election of Raymond Hill as member of the Compensation Committee7. Re-election of the Auditors8. Re-election of the Independent Voting Rights Representative9. Approval of the compensation of the members of the Board of Directors and of the Executive Management9.1. Compensation of the members of the Board of Directors 9.2. Compensation of the members of the Executive Management10. MiscellaneousThe full invitation to the AGM 2025 may be found in the General Meetings section of the Company's website here. About Addex: Addex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol 'ADXN' on each exchange. For more information, visit Contacts: Tim DyerChief Executive OfficerTelephone: +41 22 884 15 55PR@ Mike SinclairPartner, Halsin Partners+44 (0)7968 022075msinclair@ Addex Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Addex Therapeutics' Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking in to access your portfolio

Addex Convenes Annual General Meeting 2025
Addex Convenes Annual General Meeting 2025

Yahoo

timean hour ago

  • Yahoo

Addex Convenes Annual General Meeting 2025

Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2025 Annual General Meeting will take place on Tuesday June 24, 2025, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). Agenda 1. Approval of the Annual Report, the Annual Financial Statements and the Consolidated Financial Statements for the business year 20242. Consultative vote on the Compensation Report for the business year 20243. Appropriation of the results4. Discharge of the members of the Board of Directors and of the Executive Management5. Re-elections of the members of the Board of Directors and re-election of the Chairman of the Board of Directors5.1. Re-election of Vincent Lawton as member and Chairman of the Board of Directors5.2. Re-election of Raymond Hill as member of the Board of Directors5.3. Re-election of Timothy Dyer as member of the Board of Directors5.4. Re-election of Roger Mills as member of the Board of Directors5.5. Re-election of Jake Nunn as member of the Board of Directors5.6. Re-election of Isaac Manke as member of the Board of Directors6. Re-elections of the members of the Compensation Committee6.1. Re-election of Vincent Lawton as member of the Compensation Committee6.2. Re-election of Raymond Hill as member of the Compensation Committee7. Re-election of the Auditors8. Re-election of the Independent Voting Rights Representative9. Approval of the compensation of the members of the Board of Directors and of the Executive Management9.1. Compensation of the members of the Board of Directors 9.2. Compensation of the members of the Executive Management10. MiscellaneousThe full invitation to the AGM 2025 may be found in the General Meetings section of the Company's website here. About Addex: Addex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol 'ADXN' on each exchange. For more information, visit Contacts: Tim DyerChief Executive OfficerTelephone: +41 22 884 15 55PR@ Mike SinclairPartner, Halsin Partners+44 (0)7968 022075msinclair@ Addex Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Addex Therapeutics' Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store